---
title: "CLARITY MEDICAL received the resumption guidance from the Stock Exchange and continues to be suspended"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/242612948.md"
description: "CLARITY MEDICAL received the resumption guidance from the Stock Exchange on May 20, 2025, requiring an independent forensic investigation, proof of management's integrity and capability without doubt, an internal control review, compliance with listing rules, and the release of important information to the market. The company's shares remain suspended"
datetime: "2025-05-30T14:21:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/242612948.md)
  - [en](https://longbridge.com/en/news/242612948.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/242612948.md)
---

> 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/242612948.md) | [English](https://longbridge.com/en/news/242612948.md)


# CLARITY MEDICAL received the resumption guidance from the Stock Exchange and continues to be suspended

According to the announcement from CLARITY MEDICAL (01406), on May 20, 2025, the company received a letter from the Stock Exchange containing the following resumption guidance regarding the trading of the company's shares (resumption guidance):

(i) Conduct an independent forensic investigation into the relevant allegations and related matters (including but not limited to any other allegations and/or accusations that the board may receive from time to time related to the relevant allegations);

(ii) Demonstrate that there are no reasonable regulatory concerns regarding the integrity, competence, and/or character of the management of the Group and/or any individuals who have a significant influence on the management and operations of the company, as such concerns may pose risks to investors and undermine market confidence;

(iii) Conduct an independent internal control review to demonstrate that the company has sufficient internal controls and procedures to comply with the listing rules;

(iv) Recomply with Listing Rules 3.10(1), 3.10(2), 3.10A, 3.21, 3.25, and 3.27A; and

(v) Release all material information regarding the evaluation of the company's condition by its shareholders and investors to the market.

In addition, the company's shares remain suspended

### 相關股票

- [CLARITY MEDICAL (01406.HK)](https://longbridge.com/zh-HK/quote/01406.HK.md)

## 相關資訊與研究

- [Chinese Robot Maker Inovance Picks Banks for Potential Hong Kong Listing](https://longbridge.com/zh-HK/news/281110863.md)
- [SoftMedx files HKEX next-day return, issues 16.3 million shares at HKD 0.01](https://longbridge.com/zh-HK/news/281345810.md)
- [Fact or fiction: Using a gas forge](https://longbridge.com/zh-HK/news/281260763.md)
- [Yunkang Group to Overhaul Constitution to Meet Updated Hong Kong Listing Rules](https://longbridge.com/zh-HK/news/281242969.md)
- [11:33 ETFitness, Health and Wellness Experts Team Up to 'Get Fit for No Kid Hungry' with New On-Demand Initiative](https://longbridge.com/zh-HK/news/281213207.md)